As President Joe Biden’s government overhaul stalls in Congress, tensions are mounting over what changes – if any – could come for Americans at the pharmacy counter.
A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases such as cancer, rheumatoid arthritis, and even COVID-19.
It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain, digestion problems, fatigue, and hot, red rashes.
A significant indicator of whether a patient with rheumatoid arthritis will improve over the course of disease may lie in part in their gut, according to new research from Mayo Clinic’s Center for Individualized Medicine.
Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).
Northwestern Medicine scientists have developed an antibody that they believe can be used to treat muscular dystrophy, findings that were published in Science Translational Medicine.
Today, at the American Academy of Orthopaedic Surgeons (AAOS) 2021 annual meeting, Hospital for Special Surgery (HSS) sports medicine surgeon David M. Dines, MD, participated in an instructional case lecture on practical solutions in shoulder arthroplasty for patients with substantial shoulder socket bone loss known as glenoid bone deficiency.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
A simple blood test could determine which drug and dosage is more likely to be effective against rheumatoid arthritis, potentially saving sufferers serious side effects and Australian taxpayers millions of dollars.
Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients
Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.